Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)181.61K
Market Cap
$579.53M
Enterprise Value$628.68M
Total Cash (Recent Filing)$61.06M
Total Debt (Recent Filing)$70.84M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 12, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding33,950,450
10 Day Avg. Volume121,910
30 Day Avg. Volume181,608
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit8.14
Enterprise Value/Ebitda-45.56
Forecast
1Y Price Target
$19.33Price Target Upside37.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$98.91M
Bulls Say, Bears Say
Bulls Say
Sustained RNS Revenue GrowthConsistent high-teens to mid-20s RNS revenue growth evidences durable commercial adoption and expanding procedure volume, especially at Level 4 centers. A growing installed base supports recurring component sales and clinical momentum, underpinning multiyear revenue scalability as penetration increases.
High And Improving Gross MarginsSustained >80% product gross margins for RNS indicate strong product-level economics and pricing power. High margins create room for operating leverage as sales scale, improving the path to durable profitability while funding R&D and commercial expansion without proportionate margin pressure.
Regulatory & AI Clinical MilestonesFDA PMA acceptance for IGE and strong NAUTILUS outcomes materially expand the therapy's addressable market and clinical credibility. Regulatory progress and robust clinical data lower adoption barriers long-term and, combined with AI features, strengthen differentiation versus competitors.
Bears Say
Elevated Leverage And Equity VolatilitySubstantial debt relative to equity heightens financial risk and limits flexibility for sustained commercial and R&D investment. Even with improvement, leverage constrains the company's ability to absorb slower adoption, increases refinancing risk, and can pressure strategic choices if growth or cash generation falters.
Persistent Operating Cash BurnContinued negative operating and free cash flow means the business requires external funding or sustained margin improvement to finance growth. Persistent cash consumption raises dilution and refinancing risks, and limits runway for commercialization of new indications or expanded payer access initiatives.
Market Access Required To Realize IGE RevenuesRegulatory approval alone won't guarantee sales: private payer adoption, reimbursement policies, and referral patterns are structural gating factors. Achieving meaningful revenue from a new indication will require sustained commercial investment and time, delaying near-term benefit realization.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $579.53M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is May 12, 2026 which is in 8 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.156 by $0.076.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,950,450 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.156. Following the earnings report the stock price went up 0.868%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (37.21% Upside)
$19.33 (37.21% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 583.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.04%
12-Months-Change
Fundamentals
Return on Equity
-105.67%
Trailing 12-Months
Asset Growth
104.90%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and material clinical and product progress: robust revenue growth (Q4 +24%, FY +25%), sustained RNS momentum, margin expansion, positive adjusted EBITDA and cash generation in Q4, and meaningful regulatory and AI product milestones (IGE PMA acceptance; Seizure ID submission). Offsetting items include an expected near-term adjusted EBITDA loss for 2026 (‑$9M to ‑$10M) due to front-loaded commercial investments and seasonality, the wind-down of the DIXI partnership, and the need for payer coverage work before any IGE approval translates into revenue. Overall, the positives around growth, margins, product/clinical milestones and disciplined operating leverage significantly outweigh the manageable near-term headwinds and investment-driven profitability pressure.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.33
▲(37.21% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
26.49% Insiders
9.61% Mutual Funds
<0.01% Other Institutional Investors
48.74% Public Companies and
Individual Investors